GSK to skip regulatory submissions for experimental arthritis drug
Send a link to a friend
 October 27, 2022]
(Reuters) - British drugmaker GSK
said on Thursday it would not be proceeding with regulatory submissions
of its experimental treatment for moderate-to-severe rheumatoid
arthritis (RA) after the drug failed to meet a key goal in a study.
In a late-stage study, the antibody-based drug, otilimab, did not make a
meaningful difference to improving swelling and tenderness in joints to
aid movement in patients who had not responded to other forms of
treatment before.
[to top of second column]
|
GSK (GlaxoSmithKline) logo is seen in
this illustration, August 10, 2022. REUTERS/Dado Ruvic/Illustration/File
Photo
 "The limited efficacy demonstrated does not support a suitable
benefit/risk profile for otilimab as a potential treatment for RA," the
company said in a statement.
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Sherry
Jacob-Phillips)
[© 2022 Thomson Reuters. All rights
reserved.] This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
